FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Washington, D.C. 20

OMB APPR	ROVAL
OMB Number:	3235-0287
Estimated average be	urden
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is

intended to satisfy the affirmative defense conditions of Rule 10b5Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1(c). See Instr	uction 10.			
1. Name and Add ForGrowth	ress of Reporting Pers	son [*]	2. Issuer Name and Ticker or Trading Symbol NewAmsterdam Pharma Co N.V. [NAMS]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director Officer (give title Other (specify
(Last) C/O FORBIO! GOOIMEER 2	(First) N CAPITAL PART	(Middle) NERS,	3. Date of Earliest Transaction (Month/Day/Year) 11/15/2024	below) below)
(Street) NAARDEN	P7	1411 DC	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person Form filed by More than One Reporting Person
(City)	(State)	(Zip)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 2. Transaction 2A. Deemed 4. Securities Acquired (A) or Disposed 5. Amount of 6. Ownership 7. Nature of 1. Title of Security (Instr. 3) Transaction Code (Instr. 8) Form: Direct (D) or Indirect (I) Securities Beneficially Indirect Beneficial Date (Month/Day/Year) **Execution Date**, Of (D) (Instr. 3, 4 and 5) if any (Month/Day/Year) Owned Ownership Following (Instr. 4) (Instr. 4) Reported (A) or (D) Transaction(s) (Instr. 3 and 4) ν Price Code Amount See $S^{(1)}$ 8,530(2)(3) 11/15/2024 \$25.0218(2)(3) **Ordinary Shares** 11,812,033 I D footnote(4) See $S^{(1)}$ **Ordinary Shares** 11/18/2024 33,273(5) D \$25.0786(5) 11,778,760 T footnote(4)

(e.g., puts, calls, warrants, options, convertible securities) 1. Title of 3. Transaction 3A. Deemed Execution Date, 5. Number 6. Date Exercisable and 7. Title and 8. Price of 9. Number of 10. 11. Nature Derivative Conversion Date Transaction Expiration Date Amount of Derivative Ownership of Indirect derivative Security (Instr. 3) if any (Month/Day/Year) Code (Instr. 8) Security (Instr. 5) or Exercise (Month/Day/Year) Derivative (Month/Day/Year) Securities Securities Form: Beneficial Securities Acquired Underlying Derivative Beneficially Owned Ownership (Instr. 4) Direct (D) or Indirect (I) (Instr. 4) Derivative (A) or Disposed of (D) Security Security (Instr. 3 and 4) Following Reported Transaction(s) (Instr. 3, 4 (Instr. 4) and 5) Amount Number Expiration Title Code (A) (D) Exercisable Date Shares

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Name and Address ForGrowth N		rson*
(Last)	(First)	(Middle)
C/O FORBION	CAPITAL PAR	TNERS,
GOOIMEER 2-3	35,	
(Street)		
NAARDEN	P7	1411 DC
(City)	(State)	(Zip)
1. Name and Address Forbion Capit		rson* Cooperatief U.A.
(Last)	(First)	(Middle)
C/O FORBION	CAPITAL PAR	TNERS,
GOOIMEER 2-3	35	
(Street)		
NARDEN	P7	1411 DC

(City)	(State)	(Zip)
	ress of Reporting Per Management E	
(Last) C/O FORBIO! GOOIMEER 2	(First) N CAPITAL PART 2-35	(Middle) "NERS,
(Street) NARDEN	P7	1411 DC
(City)	(State)	(Zip)
	ress of Reporting Per owth Opportun CU.A.	
(Last) C/O FORBION GOOIMEER 2	(First) N CAPITAL PART 2-35	(Middle)
C/O FORBION GOOIMEER 2	N CAPITAL PART	, ,
C/O FORBION GOOIMEER 2 (Street)	N CAPITAL PART 2-35	"NERS,
C/O FORBION GOOIMEER 2 (Street) NARDEN (City) 1. Name and Add	N CAPITAL PART 2-35 P7	1411 DC (Zip)
C/O FORBION GOOIMEER 2 (Street) NARDEN (City) 1. Name and Add Forbion Gro	P7 (State) ress of Reporting Per- Owth Managem (First) N CAPITAL PART	1411 DC (Zip) son* ent B.V. (Middle)
C/O FORBION GOOIMEER 2 (Street) NARDEN (City) 1. Name and Add Forbion Gro (Last) C/O FORBION	P7 (State) ress of Reporting Per- Owth Managem (First) N CAPITAL PART	1411 DC (Zip) son* ent B.V. (Middle)

- 1. This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by NAP PoolCo B.V. ("PoolCo") on March 28, 2024.
- 2. Represents 3,746 shares sold on behalf of Forbion Growth Opportunities Fund I Cooperatief U.A. ("Forbion Growth I") and 4,784 shares sold on behalf of Forbion Capital Fund IV Cooperatief U.A. ("Forbion IV"). The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of \$25.00 to \$25.115. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
- 3. (Continued from footnote 2) Following the reported transaction, of the 11,812,033 Ordinary Shares beneficially owned by ForGrowth NAP B.V. ("ForGrowth"), 652,173 shares are directly owned by ForGrowth on behalf of Forbion Growth I, and 11,159,860 are held by PoolCo and are allocated to ForGrowth, of which in 4,535,365 shares are beneficially owned by Forbion Growth I and 6,624,495 shares are beneficially owned by Forbion IV.
- 4. For Growth is a shareholder of Pool Co. For Growth is a joint investment vehicle wholly owned by Forbion Growth I and Forbion IV but does not exercise voting or dispositive power over the Ordinary Shares held on behalf of Forbion Growth I and Forbion IV. Forbion IV Management B.V. is the sole director of Forbion Growth I. Each of the Reporting Persons disclaims Section 16 beneficial ownership of such shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any of the Reporting Persons are the beneficial owner of such shares for Section 16 or any other purpose.
- 5. Represents 14,614 shares sold on behalf of Forbion Growth I and 18,659 shares sold on behalf of Forbion IV. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of \$25.00 to \$25.28. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Following the reported transaction, of the 11,778,760 Ordinary Shares beneficially owned by ForGrowth, 652,173 shares are directly owned by ForGrowth on behalf of Forbion Growth I, and 11,126,587 are held by PoolCo and are allocated to ForGrowth, of which in 4,520,751 shares are beneficially owned by Forbion Growth I and 6,605,836 shares are beneficially owned by Forbion IV.

FORGROWTH NAP B.V., By: Forbion International Management B.V., its 11/19/2024 Director, By: /s/ V. van Houten and /s/ G.J. Mulder, its **FORBION CAPITAL FUND** IV COOPERATIEF U.A., By: Forbion IV Management B.V., its Director, By: FCPM III 11/19/2024 Services B.V., its Director, By: /s/ V. van Houten and /s/ G.J. Mulder, its Directors **FORBION IV** MANAGEMENT B.V., By: FCPM III Services B.V., its 11/19/2024 Director, By: /s/ V. van Houten and /s/ G.J. Mulder, its Directors **FORBION GROWTH** 11/19/2024

OPPORTUNITIES FUND I
COOPERATIEF U.A., By:
Forbion Growth Management
B.V., its Director, By: FCPM
III Services B.V. its Director,
By: /s/ V. van Houten and /s/
G.J. Mulder, its Directors
FORBION GROWTH
MANAGEMENT B.V., By:
FCPM III Services B.V., its

11/19/2024

<u>Director, By: /s/ V. van</u> <u>Houten and /s/ G.J. Mulder, its</u>

Directors

** Signature of Reporting Person

Data

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.